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Infection with human T-lymphotropic virus type 1 (HTLV-1)
can be associated with hematologic malignancy, inﬂammato-
ry syndromes, or infectious complications. Herein, we bring
attention to HTLV-1 infection complications as we discuss a
case of disseminated cryptococcosis in a patient with HTLV-
1-associated T cell lymphoma.
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CASE REPORT
An 82-year-old woman, originally from the Caribbean, present-
ed with fever and hemoptysis. She had no known comorbidities
and she was not receiving immunosuppressive agents. A com-
puted tomography of her thorax demonstrated extensive right
middle lobe consolidation with satellite nodular lesions. She
was treated empirically with piperacillin-tazobactam for necro-
tizing pneumonia with improvement of her symptoms. Ten
days later, she was readmitted to the hospital after developing
aphasia and confusion. On examination she was afebrile, ob-
tunded, and she quickly became unresponsive. White blood
cell count was 5600/mm3 and CD4+ T cell count was 758
cells/mm3. Human immunodeﬁciency virus (HIV) type 1 and
2 antibody testing in blood was negative. Lumbar puncture
demonstrated normal opening pressure, and cerebrospinal
ﬂuid analysis showed 105 white blood cells/mm3, 79% lympho-
cytes and 17% polymorphonuclear cells, and normal protein
and glucose levels. Magnetic resonance imaging of her brain
did not show any masses, edema, or hemorrhage. An electroen-
cephalogram revealed high theta activity, compatible with non-
convulsive status epilepticus.
Careful examination of a peripheral blood smear (Figure 1)
showed cells with petal-shaped nuclei, known as ﬂower cells,
which are frequently, but not exclusively, seen in human T-lym-
photropic virus type 1 (HTLV-1) infection or HTLV-1-associ-
ated T cell leukemia/lymphoma [1]. Visualization of round
yeasts without pseudohyphae on Gram stain from cerebrospinal
ﬂuid suggested cryptococcal infection (Figure 2). Serum and ce-
rebrospinal ﬂuid cryptococcal antigens were detected, at titers
higher than 1:64; cerebrospinal ﬂuid and bronchoalveolar la-
vage ﬂuid cultures yielded Cryptococcus neoformans variant
neoformans. Human T-lymphotropic virus type 1 antibodies
were detected in blood. Flow cytometry immunophenotyping
and T cell receptor rearrangement studies from blood were con-
sistent with adult T cell lymphoma. The above results established
the diagnosis of disseminated cryptococcosis in the setting of
HTLV-1-associated lymphoma. Despite treatment with ampho-
tericin deoxycholate combined with ﬂucytosine, and aggressive
supportive care, she had no neurologic recovery and expired
after transition to comfort care. Although the reasons for her clin-
ical deterioration despite treatment remain uncertain, it is possible
that overwhelming disseminated infection with multiorgan in-
volvement contributed to rapid decline in this immunocompro-
mised host.
DISCUSSION
Cryptococcal infection may occur in HIV-infected individuals,
organ transplant recipients, or otherwise immunocompromised
patients. There are only very rare published reports of invasive
cryptococcal disease in patients with HTLV-1-associated T cell
leukemia/lymphoma [2]. Overall, cryptococcal disease seems to
be a rare complication in HTLV-1-associated leukemia/lym-
phoma, although a potential association between cryptococco-
sis and HTLV-1 carrier state has been suggested [3, 4].
Cryptococcus neoformans variant neoformans and predomi-
nantly Cryptococcus neoformans variant gattii may also infect
seemingly immunocompetent hosts [5]. Clinically, infection
with either pathogen manifests similarly [6]. Acquisition occurs
via the respiratory route, and pulmonary infection and dissem-
ination to the central nervous system is common. Therefore, in
case of pulmonary cryptococcosis in immunosuppressed hosts,
it is important to exclude meningitis with lumbar puncture,
because the presence of central nervous system disease alters
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the dose, duration of therapy, and need for intracranial pressure
monitoring [7]. In large studies, involving mostly immunocom-
promised individuals, mortality of cryptococcal meningoen-
cephalitis remains high, up to 20%, despite treatment with
antifungal agents [8].
Although Cryptococcus species have a global distribution,
HTLV-1 epidemiology has mostly clustered in Japan, sub-
Saharan Africa, the Caribbean, and Latin America [9]. Apart
from T cell leukemia/lymphoma and inﬂammatory syndromes,
HTLV-1 infection has been associated with infectious compli-
cations such as strongyloidiasis, tuberculosis, and leprosy [9].
HTLV-1-associated decrease in type 2 helper T cell response
and HTLV-1-associated malignant transformation of T cells
are thought to predispose to parasitic infections and abnormal
cellular immune responses, respectively [9, 10]. Retroviral coin-
fection with HTLV and HIVmay also lead to increased frequen-
cy of HTLV-1-related neurological complications such as
myelopathy [11]. Nonetheless, because most HTLV-1-infected
individuals remain asymptomatic and T cell counts are normal,
there are no established guidelines in monitoring HTLV-1-in-
fected hosts for opportunistic infections. Serological testing,
based on epidemiologic suspicion, allows diagnosis and there-
fore can lead to decreased transmission of the virus, which
takes place sexually, as a blood-borne infection, or from moth-
er-to-child through breastfeeding [9]. In addition, knowledge of
HTLV-1 infection may raise clinical suspicion for coinfection
with another pathogen when HTLV-1-infected individuals
seek care [12].
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Figure 1. Peripheral blood smear, the arrow is pointing to a ﬂower cell,
which is a lymphocyte with petal-shaped nucleus. Flower cells may be
seen in the setting of HTLV-1 infection or HTLV-1-associated T cell leuke-
mia/lymphoma.
Figure 2. Cerebrospinal ﬂuid Gram stain (magniﬁcation, x1000). The
arrow is indicating an encapsulated yeast. Culture subsequently grew Cryp-
tococcus neoformans.
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